Compare Incyte Corporation (INCY) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Venture Global Inc. Class A common stock — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while Venture Global Inc. Class A common stock trades at $13.25 (market cap $32.63B). The key difference: Venture Global Inc. Class A common stock is the larger of the two by market cap, and Venture Global Inc. Class A common stock pays a 1.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Venture Global Inc. Class A common stock for 0 Days on average.
| INCY | VG | |
|---|---|---|
Market Cap | $22.99B | $32.63B |
Volume | 1,274,487 | 11,874,428 |
Sector | Health | Energy |
52-Week High | $129.93 | $17.53 |
52-Week Low | $83.80 | $5.92 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.50B | $72.01B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
